These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31291153)

  • 1. Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses.
    Carlock MA; Ingram JG; Clutter EF; Cecil NC; Ramgopal M; Zimmerman RK; Warren W; Kleanthous H; Ross TM
    Hum Vaccin Immunother; 2019; 15(9):2030-2043. PubMed ID: 31291153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains.
    Nuñez IA; Carlock MA; Allen JD; Owino SO; Moehling KK; Nowalk P; Susick M; Diagle K; Sweeney K; Mundle S; Vogel TU; Delagrave S; Ramgopal M; Zimmerman RK; Kleanthous H; Ross TM
    PLoS One; 2017; 12(11):e0185666. PubMed ID: 29091724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal assessment of human antibody binding to hemagglutinin elicited by split-inactivated influenza vaccination over six consecutive seasons.
    Carlock MA; Allen JD; Hanley HB; Ross TM
    PLoS One; 2024; 19(6):e0301157. PubMed ID: 38917104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
    Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgA Responses Following Recurrent Influenza Virus Vaccination.
    Abreu RB; Clutter EF; Attari S; Sautto GA; Ross TM
    Front Immunol; 2020; 11():902. PubMed ID: 32508822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination.
    Manenti A; Tete SM; Mohn KG; Jul-Larsen Å; Gianchecchi E; Montomoli E; Brokstad KA; Cox RJ
    Vaccine; 2017 Jan; 35(1):191-198. PubMed ID: 27789145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the vaccine-induced influenza B virus hemagglutinin-specific antibody dependent cellular cytotoxicity response.
    de Vries RD; Nieuwkoop NJ; Krammer F; Hu B; Rimmelzwaan GF
    Virus Res; 2020 Feb; 277():197839. PubMed ID: 31837382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
    Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
    Front Immunol; 2018; 9():2465. PubMed ID: 30405641
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
    Greenberg DP; Robertson CA; Talbot HK; Decker MD
    Hum Vaccin Immunother; 2017 Sep; 13(9):2058-2064. PubMed ID: 28700265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The humoral response to live and inactivated influenza vaccines administered alone and in combination to young adults and elderly.
    Stepanova L; Naykhin A; Kolmskog C; Jonson G; Barantceva I; Bichurina M; Kubar O; Linde A
    J Clin Virol; 2002 Apr; 24(3):193-201. PubMed ID: 11856620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
    Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Local antibody immune responses in influenza patients and persons vaccinated with seasonal, pre-pandemic, and pandemic live attenuated influenza vaccines].
    Donina SA; Petukhova GD; Koren'kov DA; Grigor'eva EP; Kuznetsova SA; Losev IV; Rudenko LG; Naĭkhin AN
    Vopr Virusol; 2013; 58(3):37-42. PubMed ID: 24006632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
    Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.
    Skowronski DM; Janjua NZ; Sabaiduc S; De Serres G; Winter AL; Gubbay JB; Dickinson JA; Fonseca K; Charest H; Bastien N; Li Y; Kwindt TL; Mahmud SM; Van Caeseele P; Krajden M; Petric M
    J Infect Dis; 2014 Jul; 210(1):126-37. PubMed ID: 24446529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.
    Camilloni B; Neri M; Lepri E; Iorio AM
    Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DEVELOPMENT OF THE QUADRIVALENT LIVE ATTENUATED INFLUENZA VACCINE INCLUDING TWO INFLUENZA B LINEAGES--VICTORIA AND YAMAGATA].
    Desheva YA; Smolonogina TA; Doroshenko EM; Rudenko LG
    Vopr Virusol; 2016; 61(1):16-20. PubMed ID: 27145595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemagglutinin and Neuraminidase Antibodies Are Induced in an Age- and Subtype-Dependent Manner after Influenza Virus Infection.
    Wong SS; Waite B; Ralston J; Wood T; Reynolds GE; Seeds R; Newbern EC; Thompson MG; Huang QS; Webby RJ;
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S; Nauta J; Montomoli E; Weckx J
    Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.